Heptares Therapeutics, a clinical-stage biopharmceutical company and wholly owned subsidiary of Sosei Group Corporation, and Kymab Limited, a human monoclonal antibody biopharmaceutical company, have entered into a strategic collaboration to discover, develop and commercialize antibody therapeutics targeting a number of G protein-coupled receptors (GPCR) with an initial focus on immuno-oncology.

Under the agreement, Heptares will apply its StaR platform to create stable antigens based on multiple GPCR targets chosen by the companies. Kymab will then use its Kymouse human antibody discovery platform to generate antibodies in response to immunization with these antigens. The companies will jointly conduct and share the costs of each antibody discovery and development program.

Source; Heptares Therapeutics